Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 66, Status: Authorised
We are delighted to announce a new partnership between EFIM and AMBOSS, a leading medical knowledge platform known for its high-quality content, innovative technology, and commitment to meeting physicians’ needs.
AMBOSS is offering exclusive Benefits for EFIM-Member Societies
All EFIM ordinary and associate member societies will receive special, ongoing benefits for their members:
Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 55, Status: Authorised
Annex to 22-25 April 2025 CHMP Minutes
Minutes of the CHMP meeting 22-25 April 2025
CHMP PROM minutes for the meeting on 17 February 2025
Quarterly System Demo – Q3 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2025, 09:00 (CEST) to 17 September 2025, 12:45 (CEST)
Human medicines European public assessment report (EPAR): Syfovre, pegcetacoplan, Status: Application withdrawn
Everolimus product-specific bioequivalence guidance